SLU-PP-332 vs MOTS-c: Comparing Exercise Mimetics for Metabolic Medicine

Two Compounds, Two Very Different Approaches

SLU-PP-332 and MOTS-c are both discussed under the umbrella of “exercise mimetics” — compounds that reproduce some of the metabolic benefits of exercise. They arrive at that descriptor through distinctly different biological routes, and the implications for clinical development, safety, and potential use are meaningfully different.

This comparison is for clinicians evaluating how the two compounds fit in the broader metabolic-medicine toolbox.

Mechanism

SLU-PP-332 is a small-molecule pan-agonist of the estrogen-related receptor (ERR) family — ERRα, ERRβ, and ERRγ. These nuclear receptors regulate transcription of genes involved in mitochondrial biogenesis, oxidative phosphorylation, and fatty acid oxidation. Activation reproduces part of the downstream exercise transcriptional program, particularly in skeletal muscle.

MOTS-c is a mitochondrially encoded peptide — a 16-amino-acid peptide whose coding sequence is located in the mitochondrial genome rather than the nuclear genome. MOTS-c has been characterized as a regulator of metabolic homeostasis, acting through pathways that include AMPK activation and improved insulin sensitivity. It is often described as part of a growing class of “mitochondrial-derived peptides.”

The two work at different levels — SLU-PP-332 at the nuclear receptor / transcription factor level, MOTS-c at the AMPK and insulin-signaling level. Both end up influencing skeletal muscle metabolic function, but via distinct upstream points.

Evidence Base

SLU-PP-332. Primarily preclinical. Mouse studies show improved endurance, fatty acid oxidation, and mitochondrial biogenesis markers. A notable cardiovascular signal — increased resting heart rate — has been reported in multiple experiments. No completed, results-reported phase 1 trial with a published dataset is publicly established as of 2026.

MOTS-c. A substantially longer preclinical track record, with a growing set of early human studies and commercial interest. The safety profile, as described in published work to date, has been more benign than SLU-PP-332’s. Some 503A compounding access has existed, though status can shift with PCAC review cycles and the FDA’s April 2026 bulk drug substances update deserves current verification.

Clinical Readiness

SLU-PP-332. Not FDA-approved, not on the 503A list. No legitimate clinical or compounding access.

MOTS-c. Not FDA-approved as a commercial pharmaceutical, but the compounding landscape has historically provided physician access pathways in some jurisdictions and formulations. Current status should be verified against the most recent FDA and PCAC actions.

Safety Profile

SLU-PP-332. Preclinical heart rate increase is the most prominent flag. Long-term safety, oral bioavailability, and cardiac structural implications are open questions.

MOTS-c. The published safety profile has been described as favorable, with the usual caveat that data are predominantly preclinical with limited human follow-up. Large-scale post-marketing-style safety data do not exist.

Where Each Fits — Today

For the metabolic medicine practitioner today, neither compound is a mainstream clinical tool. SLU-PP-332 is functionally not accessible through legitimate channels. MOTS-c may be accessible through compounding in some contexts, but status changes with regulatory review.

For patients seeking exercise-mimetic benefits through clinically available pathways today, the alternatives that physicians can actually deploy include:

• Structured exercise prescription itself, where feasible
• GLP-1 and related weight-management pharmacotherapy for metabolic and body composition effects
• Growth hormone axis support (CJC-1295, ipamorelin, tesamorelin) for body composition
• Mitochondrial cofactor supplementation (NAD+ precursors, CoQ10, etc.) for oxidative support
• Methylene blue for mitochondrial electron transport support

Comparison at a Glance

Axis
SLU-PP-332
MOTS-c


Class
Small molecule
Mitochondrial-derived peptide


Mechanism
Pan-ERR agonist
AMPK / insulin signaling


Primary effect
Endurance, fatty acid oxidation, mitochondrial biogenesis
Metabolic homeostasis, insulin sensitivity


Evidence base
Preclinical, mouse
Broader preclinical, some early human


Notable safety signal
Increased resting heart rate
None prominent


Oral bioavailability
Limited
Formulation-dependent


FDA status
Not approved
Not approved


503A compounding
Not listed
Status varies; verify

Key Takeaways

• SLU-PP-332 and MOTS-c work through different mechanisms despite both being discussed as “exercise mimetics.”
• MOTS-c has a broader preclinical and early clinical track record.
• SLU-PP-332’s cardiovascular signal is a meaningful open safety question.
• Neither compound is an established first-line clinical tool as of 2026.
• For patients seeking exercise-mimetic effects, established clinical alternatives should be the first conversation.

Frequently Asked Questions

Are SLU-PP-332 and MOTS-c the same class of compound?

No. SLU-PP-332 is a small molecule that activates nuclear receptors; MOTS-c is a peptide encoded in the mitochondrial genome. They operate at different levels of metabolic regulation.

Which has more clinical evidence?

MOTS-c has a longer and broader preclinical track record with some early human study activity. SLU-PP-332’s published data are predominantly preclinical mouse work.

Can I get either through a [compounding pharmacy](https://newtropin.com/services/compound-pharmacy/) in 2026?

SLU-PP-332 is not on the 503A list. MOTS-c availability varies by the current PCAC review status and state regulation; verify against the most recent FDA action.

Are they safe together?

Combined use has not been characterized and is not an established clinical protocol.